

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/235715980>

Azide-alkyne cycloaddition en route to 1H-1,2,3-triazole-tethered 7-chloroquinoline-isatin chimeras: Synthesis and antimalarial evaluation

ARTICLE *in* EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY · FEBRUARY 2013

Impact Factor: 3.45 · DOI: 10.1016/j.ejmech.2013.01.032 · Source: PubMed

CITATIONS

27

READS

74

6 AUTHORS, INCLUDING:



Parvesh Singh

University of KwaZulu-Natal

55 PUBLICATIONS 294 CITATIONS

SEE PROFILE



Vipin Kumar

Guru Nanak Dev University

85 PUBLICATIONS 738 CITATIONS

SEE PROFILE



Short communication

Azide-alkyne cycloaddition *en route* to 1*H*-1,2,3-triazole-tethered 7-chloroquinoline-isatin chimeras: Synthesis and antimalarial evaluationRaghu Raj^a, Pardeep Singh^a, Parvesh Singh^b, Jiri Gut^c, Philip J. Rosenthal^c, Vipin Kumar^{a,*}^a Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India^b Department of Chemistry, Durban University of Technology, Durban 4000, South Africa^c Department of Medicine, University of California, San Francisco, CA, USA

ARTICLE INFO

Article history:

Received 12 December 2012

Received in revised form

22 January 2013

Accepted 26 January 2013

Available online 5 February 2013

Keywords:

7-Chloroquinoline-isatin conjugates

1*H*-1,2,3-triazole

Antimalarial evaluation

Structure–activity relationship

ABSTRACT

We describe the synthesis and antimalarial activities of 1*H*-1,2,3-triazole tethered 7-chloroquinoline-isatin hybrids. Activity against cultured parasites was dependent on the C-5 substituent of the isatin ring as well as the alkyl chain length between the isatin and 7-chloroquinoline moieties. Compound **8h**, with an optimum alkyl chain length ($n = 3$) and a chloro substituent at the C-5 position of the isatin ring, displayed the best activity among the test compounds, with IC₅₀ value of 1.21 μ M against cultured W2-strain *Plasmodium falciparum*.

© 2013 Elsevier Masson SAS. All rights reserved.

1. Introduction

With approximately 500 million infections and 2.5 million deaths annually [1], malaria remains one of the most serious health problems of the developing world. The causative agent of the most lethal form of malaria, *Plasmodium falciparum*, has developed resistance to multiple drugs including chloroquine (CQ), previously the first line drug to treat malaria in most endemic countries [2]. CQ induces heme accumulation in the parasite digestive vacuole, leading to parasite death, possibly through degradation of parasite membranes [3]. CQ resistance is now very common, and largely due to mutations in the *P. falciparum* CQ resistance transporter (pfcr1) gene, which encodes the protein believed to mediate efflux of the drug from the digestive vacuole of the parasite, leading to sub-optimal drug concentrations [4]. The parasite has also developed resistance to other antimalarials, including cycloguanil and pyrimethamine, which are specific inhibitors of *P. falciparum* dihydrofolate reductase (PfDHFR) [5]. The most important newer drugs to treat malaria are artemisinin and its semi-synthetic derivatives,

which offer rapid and potent antimalarial activity. These drugs are best used in combination with other agents as components of artemisinin-based combination therapy (ACT) [6]. However, the first cases of clinical resistance to artemisinins were reported recently from the Thai–Cambodian border, with delayed clearance of parasites after treatment with ACTs, providing strong impetus for the development of new antimalarials [7].

The approaches currently being adopted to overcome the challenges of multi-drug resistance in *P. falciparum* include combination therapy, developing analogues of the existing drugs as well as drug resistance reversers [8]. In addition, molecular hybridization, which involves the rational design of new chemical entities by covalent fusion of two or more drugs, active compounds and/or pharmacophoric units with complimentary activities and multiple pharmacological targets, is an attractive strategy. Different and/or dual modes of action of hybrid components may optimize anti-malarial efficacy and reduce undesired side effects [9]. This strategy has resulted in the development of trioxane-aminoquinoline [10], artemisinin-quinine [11] and ferrocene-CQ chimeras [12] with improved antimalarial activity compared to the parent drugs.

Isatin (1*H*-indole-2,3-dione) is a promising new class of heterocyclic molecules with many promising activity profiles and good tolerance in humans [13,14]. The 2-oxindole derivatives SU-5416

* Corresponding author. Tel.: +91 183 2258802 09x3320; fax: +91 183 2258819 20.

E-mail address: vipan_org@yahoo.com (V. Kumar).

(semaxanib) and SU-11248 (sunitinib) reportedly have tyrosine kinase inhibitory and anti-angiogenic properties [15]. Schiff and Mannich bases of isatin are reported to exhibit broad antimicrobial properties, including antiviral [16], anti-mycobacterial [17], anti-fungal, and antibacterial activities [18]. A recent report by our group described the synthesis of 3-methylene-substituted indolinones and their antimalarial activities. Indolinones containing a Leu-i-amylyl recognition moiety were found to be modest inhibitors of the *P. falciparum* cysteine protease falcipain-2, and displayed *in vitro* activity against the chloroquine-resistant *P. falciparum* W2 strain in the low micromolar range [19].

Recent disclosures from our laboratory have described the utilization of molecular hybridization towards the synthesis of β -lactam-7-chloroquinoline conjugates and evaluation of their antimalarial profiles. Activity against cultured *P. falciparum* was observed to be dependent on the *N*-substituent of the β -lactam ring as well as the presence of bis-triazole at the C-3 position. The observed activity profiles were further corroborated *via* docking simulations performed using the ligand fit module [20]. With our interest in the synthesis of novel molecular frameworks utilizing hybridization protocols [21], we sought to synthesize 1*H*-1,2,3-triazole-tethered-7-chloroquinoline-isatin conjugates with or without a well modulated alkyl chain, as depicted in Fig. 1, and to evaluate their antimalarial activity. The triazole functionality was introduced because of its favourable properties, including moderate dipole character, hydrogen bonding capability, rigidity and stability under *in vivo* conditions, which are evidently responsible for its diverse biological activities [22].

2. Result and discussions

2.1. Synthetic chemistry

The synthetic protocol utilized for the synthesis of desired hybrids involved well established Cu-mediated click chemistry of *N*-propargylated isatins with varied substitutions and 7-chloroquinoline based azides with or without a spacer consisting of a well modulated alkyl chain length. The precursor, *N*-propargylated isatins **1** were synthesized by treating a solution of corresponding isatin in DMF with sodium hydride (NaH), resulting in the formation of intensely purple coloured anion that was

subsequently reacted with propargyl bromide [23]. 4-Azido-7-chloroquinoline **2**, another precursor, was prepared by applying the method described by de Souza et al. [24], whereby 4,7-dichloroquinoline was reacted with 2 equiv of NaN₃ in anhydrous DMF at 65 °C for 6 h. The desired hybrids **3** were prepared *via* room temperature stirring of **1** with **2** in the presence of copper sulphate and sodium ascorbate in a C₂H₅OH:H₂O (90:10) mixture (Scheme 1).

(2-Azido-ethyl/propyl)-(7-chloro-quinolin-4-yl)-amine **7**, required for the synthesis of the desired hybrids, was prepared by initially reacting 4,7-dichloroquinoline with ethanolamine or 1-propanol amine at 120 °C for 12 h, followed by mesylation with methane sulphonyl chloride at 0 °C for 2–3 h [25]. The mesylated product **6** was treated with sodium azide at 120 °C in dry DMF for 12 h, resulting in the isolation of desired precursors **7** as depicted in Scheme 2. The targeted bifunctional hybrids **8a–j** were synthesized by room temperature stirring of precursors **7** and propargylated isatins **2** in a C₂H₅OH:H₂O (9:1) mixture in the presence of CuSO₄·5H₂O and sodium ascorbate for 7 h. The progress of reactions was monitored using TLC. The reactions resulted in the isolation of crude products which were recrystallized using (9:1) CHCl₃:MeOH mixture.

The structure of the hybrids **3** and **8** were assigned on the basis of spectral data and analytical evidence. For example, **8c**, showed a molecular ion peak [M + H]⁺ at 460.2432, along with characteristic peaks in ¹H and ¹³C NMR spectra. The ¹H NMR spectrum exhibited characteristic peaks at δ 3.71, 4.57 and 4.85 corresponding to methylene protons, a singlet at δ 7.77 corresponding to 1H of a triazole ring proton, along with the characteristic 7-chloroquinoline ring protons. The appearance of the requisite number of carbons in the ¹³C NMR spectrum along with the two characteristic peaks at δ 159.6 and 182.4 assigned to isatin ring carbonyls further corroborated the assigned structure.

2.2. Methods for assessment of antimalarial activity of test compounds

The W2 strain of *P. falciparum* was cultured in RPMI-1640 medium with 10% human serum, following standard methods, and parasites were synchronized with 5% D-sorbitol [26]. Beginning at the ring stage, microwell cultures were incubated with different





Fig. 1. General structure of lead compound and target hybrid compounds.



Scheme 1. Synthesis of 7-chloroquinoline-isatin-conjugates **3a–e**.


concentrations of compounds for 48 h. The compounds were added from DMSO stocks; the maximum concentration of DMSO used was 0.1%. Controls without inhibitors included 0.1% DMSO. After 48 h when control cultures had progressed to new rings, the culture medium was removed, and cultures were incubated for 48 h with 1% formaldehyde in PBS, pH 7.4, at room temperature. Fixed parasites were then transferred to 0.1% Triton X-100 in PBS containing 1 nM YOYO-1 dye (Molecular Probes). Parasitaemia was determined from dot plots (forward scatter vs. fluorescence) acquired on a FACSort flow cytometer using Cell Quest software (Beckton Dickinson). IC₅₀ values for growth inhibition were determined from plots of percent control parasitaemia over inhibitor concentration using the Prism 3.0 program, (GraphPad Software), with data from duplicate experiments fitted by nonlinear regression [27].

2.3. In vitro antiplasmodial activity

The test compounds were evaluated for their antimalarial profiles against the CQ resistant W2 strain of *P. falciparum*. The hybrids **3a–e** were inactive at tested concentrations, while **8a–j**, with varied alkyl chain length between the 7-chloroquinoline and isatin groups, showed better antiplasmodial activity (Table 1). Although the test compounds were not as active as standard drugs viz. chloroquine (CQ) and artemisinin (ART), an interesting structure–activity relationship (SAR) has been observed. Analysis of Table 1 reveals the effects of the substituent on the C-5 position of isatin

as well as the alkyl chain length on antimalarial activity. Comparing the bifunctional hybrids **8a–e** ($n = 2$), **8c**, with a chloro-substituent at the C-5 position of the isatin ring, displayed the best IC₅₀ value (1.37 μM), while the introduction of a strong electron withdrawing fluoro substituent decreased activity, as evidenced by **8b**. The C-5 unsubstituted hybrid **8a** showed the least activity of this series against *P. falciparum*, with an IC₅₀ of 3.07 μM. A similar comparison of series **8f–j** ($n = 3$) showed a similar trend, with **8h** (R = Cl) the most potent among the test compounds, with an IC₅₀ of 1.21 μM. The C-5 unsubstituted hybrid **8f** again proved to be least active in the series in inhibiting plasmodial growth, with an IC₅₀ of 3.85 μM, emphasizing the role of the substituent at the C-5 position of the isatin ring. Thus, antimalarial efficacy showed improvement with increase in chain length, except in hybrids with unsubstituted isatin (**8a** and **8f**).

In conclusion, we report the synthesis of 1*H*-1,2,3-triazole tethered isatin-7-chloroquinoline hybrids along with evaluation of their antiplasmodial activity. The activity profiles showed dependence on the substituents at the C-5 position of isatin as well as the length of the alkyl chain. Compound **8h**, with an optimum combination of longer alkyl chain length ($n = 3$) and a chloro substituent at the C-5 position of the isatin ring, displayed the best activity among the test compounds. Further work on the diversification of these conjugates via elaboration of alkyl chain length and introduction of halogen functionalities on the isatin ring is underway.



Scheme 2. Synthesis of 7-chloroquinoline-isatin-conjugates **8a–j**.

Table 1
Antimalarial activity results of tested compounds.

Compound	Structure	W2 (CQ-R) ^a IC ₅₀ (μM)
3a		>5
3b		>5
3c		>5
3d		>5
3e		>5
8a		3.07
8b		2.30
8c		1.37
8d		1.73
8e		1.63

Table 1 (continued)

Compound	Structure	W2 (CQ-R) ^a IC ₅₀ (μM)
8f		3.85
8g		1.35
8h		1.21
8i		1.66
8j		1.30
Chloroquine(CQ)		0.099
Artemisinin (ART)		0.014

^a CQ-R: Chloroquine resistant.

3. Experimental section

Melting points were determined by open capillary using a Veego Precision Digital Melting Point apparatus (MP-D) and are uncorrected. IR spectra were recorded on a Shimadzu D-8001 spectrophotometer. ¹H NMR spectra were recorded in deuteriochloroform and dimethylsulfoxide-*d*₆ with a Jeol 300 (300 MHz) spectrometer using TMS as an internal standard. Chemical shift values are expressed as parts per million downfield from TMS and *J* values are in hertz. Splitting patterns are indicated as s: singlet, d: doublet, t: triplet, m: multiplet, dd: double doublet, ddd: doublet of a doublet of a doublet, and br: broad peak. ¹³C NMR spectra were recorded on Jeol 300 (75 MHz) and BRUKER AVANCE II (400 MHz) spectrometers in dimethylsulfoxide using TMS as internal standard. High resolution mass spectra were recorded on Bruker-microTOF-Q II spectrometer.

3.1. Typical procedure for the synthesis of isatin-7-chloroquinoline conjugates (**3** or **8**)

To the stirred solution of **1** (1 mmol) and **2** or **7** (2 mmol) in 20 mL ethanol–water (10:1) was added in succession copper sulphate (0.055 mmol) and sodium ascorbate (0.143 mmol) at room temperature. On completion of the reaction, as monitored by TLC, water (15 mL) was added to the reaction mixture and extracted with chloroform (2 × 50 mL). Combined organic layers were dried over anhydrous sodium sulphate and concentrated under reduce

pressure to result in a crude product which was recrystallized using chloroform:methanol (9:1) mixture.

3.1.1. 1-[1-(7-Chloro-quinolin-4-yl)-1H-[1,2,3]triazol-4-ylmethyl]-1H-indole-2,3-dione (**3a**)

Red Solid; Yield: 85%; m.p. 240 °C (decomp.). IR (KBr) ν_{\max} : 1741, 1609 cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 5.16 (s, 2H, –N–CH₂–); 7.16 (t, J = 7.2 Hz, 1H, ArH, H^7); 7.28 (d, J = 7.8 Hz, 1H, H^9); 7.60 (d, J = 7.2 Hz, 1H, H^6); 7.67 (t, J = 7.8 Hz, 1H, H^8); 7.79 (m, 1H, H^2 + H^3); 8.00 (d, J = 9.0 Hz, 1H, H^4); 8.27 (s, 1H, H^5); 8.90 (s, 1H, triazole H); 9.12 (d, J = 4.5 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz): δ ppm = 35.2, 111.1, 111.2, 112.5, 116.6, 118.0, 120.3, 124.8, 125.3, 125.6, 128.5, 129.2, 135.4, 140.1, 142.3, 146.7, 149.8, 152.1, 158.9, 181.8. HRMS Calculated for $\text{C}_{20}\text{H}_{12}\text{N}_5\text{O}_2$ [$\text{M} + \text{H}$]⁺ 390.7946 found 390.7941.

3.1.2. 1-[1-(7-Chloro-quinolin-4-yl)-1H-[1,2,3]triazol-4-ylmethyl]-5-fluoro-1H-indole-2,3-dione (**3b**)

Red Solid; Yield: 80%; m.p. 220 °C (decomp.). IR (KBr) ν_{\max} : 1740, 1614 cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 5.16 (s, 2H, –N–CH₂–); 7.30 (dd, J = 3.9, 8.4 Hz, 1H, ArH, H^7); 7.50–7.59 (m, 2H, H^3 + H^6); 7.77 (d, J = 2.1 Hz, 1H, H^9); 7.79 (d, J = 4.5 Hz, 1H, H^2); 8.00 (d, J = 9.0 Hz, 1H, H^4); 8.27 (d, J = 2.1 Hz, H^5); 8.89 (s, 1H, triazole H); 9.12 (d, J = 4.5 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz): δ ppm = 35.0, 111.3, 111.7, 112.6, 116.8, 118.7, 120.0, 124.2, 125.4, 125.9, 128.1, 129.0, 135.4, 140.2, 142.5, 146.3, 149.4, 152.3, 158.0, 182.5. HRMS Calculated for $\text{C}_{20}\text{H}_{11}\text{ClFN}_5\text{O}_2$ [$\text{M} + \text{H}$]⁺ 408.7850 found 408.7857.

3.1.3. 5-Chloro-1-[1-(7-chloro-quinolin-4-yl)-1H-[1,2,3]triazol-4-ylmethyl]-1H-indole-2,3-dione (**3c**)

Red Solid; Yield: 68%; m.p. 198 °C (decomp.). IR (KBr) ν_{\max} : 1737, 1616 cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 5.10 (s, 2H, –N–CH₂–); 7.20 (d, J = 8.4 Hz, 1H, ArH, H^7); 7.42–7.51 (m, 2H, H^3 + H^6); 7.72 (d, J = 2.1 Hz, 1H, H^9); 7.83 (d, J = 5.1 Hz, 1H, H^2); 8.01 (d, J = 9.0 Hz, 1H, H^4); 8.28 (d, J = 2.1 Hz, H^5); 8.90 (s, 1H, triazole H); 9.10 (d, J = 5.1 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz): δ ppm = 35.7, 111.6, 111.9, 112.4, 116.2, 118.8, 120.1, 124.8, 125.2, 125.4, 128.3, 129.1, 135.7, 140.0, 142.8, 146.7, 149.1, 152.7, 157.7, 181.8. HRMS Calculated for $\text{C}_{20}\text{H}_{11}\text{Cl}_2\text{N}_5\text{O}_2$ [$\text{M} + \text{H}$]⁺ 425.2396 found 425.2390.

3.1.4. 5-Bromo-1-[1-(7-chloro-quinolin-4-yl)-1H-[1,2,3]triazol-4-ylmethyl]-1H-indole-2,3-dione (**3d**)

Red Solid; Yield: 71%; m.p. 205 °C (decomp.). IR (KBr) ν_{\max} : 1732, 1611 cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 5.09 (s, 2H, –N–CH₂–); 7.19 (d, J = 8.4 Hz, 1H, ArH, H^7); 7.39–7.48 (m, 2H, H^3 + H^6); 7.68 (d, J = 2.1 Hz, 1H, H^9); 7.78 (d, J = 5.1 Hz, 1H, H^2); 7.99 (d, J = 9.0 Hz, 1H, H^4); 8.33 (d, J = 2.1 Hz, H^5); 8.95 (s, 1H, triazole H); 9.05 (d, J = 5.1 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz): δ ppm = 34.8, 111.1, 111.7, 112.5, 116.5, 118.4, 120.9, 124.3, 125.2, 125.6, 128.0, 129.7, 135.8, 140.1, 142.9, 146.2, 149.7, 152.2, 158.1, 182.3. HRMS Calculated for $\text{C}_{20}\text{H}_{11}\text{BrClN}_5\text{O}_2$ [$\text{M} + \text{H}$]⁺ 469.6906 found 469.6901.

3.1.5. 1-[1-(7-Chloro-quinolin-4-yl)-1H-[1,2,3]triazol-4-ylmethyl]-5-methyl-1H-indole-2,3-dione (**3e**)

Red Solid; Yield: 80%; m.p. 189 °C (decomp.). IR (KBr) ν_{\max} : 1740, 1614 cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 2.29 (s, 3H, –CH₃); 5.02 (s, 2H, –N–CH₂–); 7.24 (d, J = 8.4 Hz, ArH, H^7); 7.48–7.57 (m, 2H, H^3 + H^6); 7.74 (d, J = 2.1 Hz, 1H, H^9); 7.79 (d, J = 4.5 Hz, 1H, H^2); 8.10 (d, J = 9.0 Hz, 1H, H^4); 8.26 (d, J = 2.1 Hz, H^5); 8.90 (s, 1H, triazole H); 9.04 (d, J = 4.5 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz): δ ppm = 21.8, 35.1, 111.4, 111.8, 112.3, 116.5, 118.7, 120.2, 124.1, 125.3, 125.5, 128.9, 129.6, 135.2, 140.0, 142.7, 146.8, 149.6, 152.1, 158.3, 182.1. HRMS Calculated for $\text{C}_{21}\text{H}_{14}\text{ClN}_5\text{O}_2$ [$\text{M} + \text{H}$]⁺ 404.8212 found 404.8219.

3.1.6. 1-[1-[2-(7-Chloro-quinolin-4-ylamino)-ethyl]-1H-[1,2,3]triazol-4-ylmethyl]-1H-indole-2,3-dione (**8a**)

Red Solid; Yield: 78%; m.p. 163 °C (decomp.). IR (KBr) ν_{\max} : 3328 (N–H), 1737 (C=O), 1610 (C=O) cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 3.79–3.80 (m, 2H, –N–CH₂–); 4.64–4.66 (m, 2H, –N–CH₂–); 4.95 (s, 2H, –N–CH₂–); 6.36 (d, J = 5.1 Hz, 1H, H^2); 7.09 (t, J = 7.5 Hz, 1H, ArH); 7.26–7.32 (m, 3H, ArH + H^4 + NH exchangeable with D_2O); 7.47–7.55 (m, 2H, ArH); 7.77 (s, 1H, H^5); 7.91 (s, 1H, triazole H); 8.01 (d, J = 6.9 Hz, 1H, H^3); 8.33 (d, J = 5.1 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz): δ ppm = 35.2, 42.6, 48.5, 98.0, 110.8, 112.3, 117.5, 118.0, 123.4, 123.7, 124.3, 124.5, 126.6, 133.1, 141.4, 146.5, 148.8, 149.9, 151.3, 157.2, 159.7, 182.2. HRMS Calculated for $\text{C}_{22}\text{H}_{17}\text{ClN}_6\text{O}_2$ [$\text{M} + \text{H}$]⁺ 424.7909 found 424.7902.

3.1.7. 1-[1-[2-(7-Chloro-quinolin-4-ylamino)-ethyl]-1H-[1,2,3]triazol-4-ylmethyl]-5-fluoro-1H-indole-2,3-dione (**8b**)

Red Solid; Yield: 62%; m.p. 170 °C (decomp.). IR (KBr) ν_{\max} : 3355 (N–H), 1732 (C=O), 1616 (C=O) cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 3.71–3.73 (m, 2H, –N–CH₂–); 4.57–4.59 (m, 2H, –N–CH₂–); 4.83 (s, 2H, –N–CH₂–); 6.21 (d, J = 5.4 Hz, 1H, H^2); 7.01 (dd, 1H, J = 8.4, 1.8 Hz, 1H, ArH, H^7); 7.10 (s, NH exchangeable with D_2O); 7.15 (d, J = 8.4 Hz, 1H, ArH, H^6); 7.21 (d, J = 9.0 Hz, 1H, H^4); 7.61 (d, J = 1.8 Hz, 1H, ArH, H^9); 7.71 (s, 1H, H^5); 7.85 (s, 1H, triazole H); 7.91 (d, J = 9.0 Hz, 1H, H^3); 8.21 (d, J = 5.1 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz): δ ppm = 35.4, 42.5, 48.4, 98.8, 111.1, 112.8, 117.4, 118.8, 123.0, 123.3, 124.6, 124.9, 126.5, 133.9, 141.1, 146.6, 147.8, 149.5, 150.6, 157.9, 159.7, 182.4. HRMS Calculated for $\text{C}_{22}\text{H}_{16}\text{ClFN}_6\text{O}_2$ [$\text{M} + \text{H}$]⁺ 443.7893 found 443.7899.

3.1.8. 5-Chloro-1-[1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1H-[1,2,3]triazol-4-ylmethyl]-1H-indole-2,3-dione (**8c**)

Red Solid; Yield: 71%; m.p. 177 °C (decomp.). IR (KBr) ν_{\max} : 3342 (N–H), 1732 (C=O), 1616 (C=O) cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 3.70–3.72 (m, 2H, –N–CH₂–); 4.55–4.59 (m, 2H, –N–CH₂–); 4.85 (s, 2H, –N–CH₂–); 6.22 (d, J = 5.4 Hz, 1H, H^2); 7.00 (d, 1H, J = 8.4 Hz, 1H, ArH, H^7); 7.10 (s, NH exchangeable with D_2O); 7.21 (d, J = 8.7 Hz, 1H, H^4); 7.35 (d, J = 8.4 Hz, 1H, ArH, H^6); 7.40 (d, J = 1.8 Hz, 1H, ArH, H^9); 7.68 (s, 1H, H^5); 7.77 (s, 1H, triazole H); 7.91 (d, J = 8.7 Hz, 1H, H^3); 8.21 (d, J = 5.1 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz): δ ppm = 34.9, 42.1, 48.0, 98.5, 111.5, 112.4, 117.1, 118.3, 123.8, 123.9, 124.0, 124.2, 126.9, 133.7, 141.1, 146.2, 148.2, 149.9, 151.2, 157.6, 159.6, 182.4. HRMS Calculated for $\text{C}_{22}\text{H}_{16}\text{Cl}_2\text{N}_6\text{O}_2$ [$\text{M} + \text{H}$]⁺ 460.2439 found 460.2432.

3.1.9. 5-Bromo-1-[1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1H-[1,2,3]triazol-4-ylmethyl]-1H-indole-2,3-dione (**8d**)

Red Solid; Yield: 60%; m.p. 185 °C (decomp.). IR (KBr) ν_{\max} : 3370 (N–H), 1739 (C=O), 1609 (C=O) cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 3.71–3.73 (m, 2H, –N–CH₂–); 4.58–4.60 (m, 2H, –N–CH₂–); 4.82 (s, 2H, –N–CH₂–); 6.20 (d, J = 5.4 Hz, 1H, H^2); 7.01 (dd, 1H, J = 8.4, 1.8 Hz, 1H, ArH, H^7); 7.09 (s, NH exchangeable with D_2O); 7.22 (d, J = 8.7 Hz, 1H, H^4); 7.37 (d, J = 8.4 Hz, 1H, ArH, H^6); 7.41 (d, J = 1.8 Hz, 1H, ArH, H^9); 7.70 (s, 1H, H^5); 7.79 (s, 1H, triazole H); 7.93 (d, J = 8.7 Hz, 1H, H^3); 8.22 (d, J = 5.1 Hz, 1H, H^1); ^{13}C NMR ($\text{DMSO}-d_6$, 75 MHz): δ ppm = 35.4, 42.7, 48.4, 98.5, 111.1, 112.1, 117.1, 118.9, 123.2, 123.5, 124.3, 124.7, 126.1, 133.4, 141.2, 146.4, 148.7, 149.8, 151.5, 157.8, 159.6, 182.8. HRMS Calculated for $\text{C}_{22}\text{H}_{16}\text{ClBrN}_6\text{O}_2$ [$\text{M} + \text{H}$]⁺ 504.6949 found 504.6945.

3.1.10. 1-[1-[2-(7-Chloro-quinolin-4-ylamino)-ethyl]-1H-[1,2,3]triazol-4-ylmethyl]-5-methyl-1H-indole-2,3-dione (**8e**)

Red Solid; Yield: 60%; m.p. 169 °C (decomp.). IR (KBr) ν_{\max} : 3327 (N–H), 1739 (C=O), 1609 (C=O) cm^{-1} ; ^1H NMR (300 MHz CDCl_3 + $\text{DMSO}-d_6$): δ 2.31 (s, 3H, –CH₃); 3.71–3.74 (m, 2H, –N–CH₂–); 4.57–4.59 (m, 2H, –N–CH₂–); 4.82 (s, 2H, –N–CH₂–);

6.21 (d, $J = 5.4$ Hz, 1H, H^2); 7.01 (d, 1H, $J = 8.4$ Hz, 1H, ArH, H^7); 7.09 (s, NH exchangeable with D_2O); 7.22 (d, $J = 8.7$ Hz, 1H, H^4); 7.35–7.38 (d, $J = 8.4$ Hz, 1H, ArH, H^6); 7.41 (d, $J = 1.8$ Hz, 1H, ArH, H^9); 7.70 (s, 1H, H^5); 7.79 (s, 1H, triazole H); 7.92–7.95 (d, $J = 8.7$ Hz, 1H, H^3); 8.22 (d, $J = 5.1$ Hz, 1H, H^1); ^{13}C NMR (DMSO- d_6 , 75 MHz): δ ppm = 22.2, 34.8, 42.2, 48.0, 98.3, 111.2, 112.5, 117.5, 118.2, 123.2, 123.6, 124.4, 124.8, 126.7, 133.5, 141.2, 146.1, 147.9, 149.4, 151.2, 158.1, 159.7, 181.8. HRMS Calculated for $C_{23}H_{19}ClN_6O_2$ [$M + H$] $^+$ 439.8254 found 439.8259.

3.1.11. 1-[1-[3-(7-Chloro-quinolin-4-ylamino)-propyl]-1H-[1,2,3] triazol-4-ylmethyl]-1H-indole-2,3-dione (**8f**)

Red Solid; Yield: 71%; m.p. 171 °C (decomp.). IR (KBr) ν_{max} : 3364 (N–H), 1740 (C=O), 1611 (C=O) cm^{-1} ; 1H NMR (300 MHz $CDCl_3 + DMSO-d_6$): δ 2.23–2.27 (m, 2H, $-CH_2-$); 3.78–3.80 (m, 2H, $-N-CH_2-$); 4.63–4.65 (m, 2H, $-N-CH_2-$); 4.89 (s, 2H, $-N-CH_2-$); 6.36 (d, $J = 5.1$ Hz, 1H, H^2); 7.10 (t, 1H, $J = 7.2$ Hz, 1H, ArH); 7.27–7.34 (m, 3H, ArH + H^4 + NH exchangeable with D_2O); 7.50–7.58 (m, 2H, ArH); 7.79 (s, 1H, H^5); 7.98 (s, 1H, triazole H); 8.18 (d, $J = 6.9$ Hz, 1H, H^3); 8.40 (d, $J = 5.1$ Hz, 1H, H^1); ^{13}C NMR (DMSO- d_6 , 75 MHz): δ ppm = 30.1, 36.0, 42.9, 48.8, 98.3, 111.2, 112.7, 117.5, 118.5, 123.2, 123.9, 124.4, 124.6, 126.4, 133.2, 141.6, 146.8, 148.3, 149.5, 151.6, 157.4, 159.9, 182.9. HRMS Calculated for $C_{23}H_{19}ClN_6O_2$ [$M + H$] $^+$ 447.8890 found 447.8895.

3.1.12. 1-[1-[3-(7-Chloro-quinolin-4-ylamino)-propyl]-1H-[1,2,3] triazol-4-ylmethyl]-5-fluoro-1H-indole-2,3-dione (**8g**)

Red Solid; Yield: 69%; m.p. 150–151 °C. IR (KBr) ν_{max} : 3351 (N–H), 1738 (C=O), 1617 (C=O) cm^{-1} ; 1H NMR (300 MHz $CDCl_3 + DMSO-d_6$): δ 2.24–2.28 (m, 2H, $-CH_2-$); 3.74–3.76 (m, 2H, $-N-CH_2-$); 4.58–4.60 (m, 2H, $-N-CH_2-$); 4.91 (s, 2H, $-N-CH_2-$); 6.23 (d, $J = 5.1$ Hz, 1H, H^2); 7.06 (dd, 1H, $J = 8.4, 1.8$ Hz, 1H, ArH, H^7); 7.11 (s, NH exchangeable with D_2O); 7.17 (d, $J = 8.4$ Hz, 1H, ArH, H^6); 7.25 (d, $J = 9.0$ Hz, 1H, H^4); 7.63 (d, $J = 1.8$ Hz, 1H, ArH, H^9); 7.72 (s, 1H, H^5); 7.86 (s, 1H, triazole H); 7.94 (d, $J = 9.0$ Hz, 1H, H^3); 8.22 (d, $J = 5.1$ Hz, 1H, H^1); ^{13}C NMR (DMSO- d_6 , 75 MHz): δ ppm = 29.7, 35.0, 42.2, 48.1, 98.7, 111.7, 113.4, 117.1, 118.9, 123.1, 123.6, 124.2, 124.5, 126.6, 133.7, 141.4, 146.8, 147.8, 149.7, 150.1, 158.5, 159.5, 181.6. HRMS Calculated for $C_{23}H_{18}ClFN_6O_2$ [$M + H$] $^+$ 465.8794 found 465.8788.

3.1.13. 5-Chloro-1-[1-[3-(7-chloro-quinolin-4-ylamino)-propyl]-1H-[1,2,3] triazol-4-ylmethyl]-1H-indole-2,3-dione (**8h**)

Red Solid; Yield: 68%; m.p. 153–154 °C. IR (KBr) ν_{max} : 3372 (N–H), 1741 (C=O), 1607 (C=O) cm^{-1} ; 1H NMR (300 MHz $CDCl_3 + DMSO-d_6$): δ 2.20–2.22 (m, 2H, $-CH_2-$); 3.32–3.36 (m, 2H, $-N-CH_2-$); 4.45–4.50 (m, 2H, $-N-CH_2-$); 4.97 (s, 2H, $-N-CH_2-$); 6.30 (d, $J = 5.4$ Hz, 1H, H^2); 7.10 (d, 1H, $J = 8.4$ Hz, 1H, ArH, H^7); 7.15 (s, NH exchangeable with D_2O); 7.27 (d, $J = 8.7$ Hz, 1H, H^4); 7.40 (d, $J = 8.4$ Hz, 1H, ArH, H^6); 7.48 (d, $J = 1.8$ Hz, 1H, ArH, H^9); 7.72 (s, 1H, H^5); 7.82 (s, 1H, triazole H); 7.96 (d, $J = 8.7$ Hz, 1H, H^3); 8.28 (d, $J = 5.1$ Hz, 1H, H^1); ^{13}C NMR (DMSO- d_6 , 75 MHz): δ ppm = 31.0, 35.9, 42.7, 48.3, 98.8, 111.9, 112.8, 117.4, 118.4, 123.3, 123.7, 124.1, 124.6, 126.8, 133.5, 141.4, 146.4, 148.5, 150.2, 151.6, 157.9, 159.8, 182.8. HRMS Calculated for $C_{23}H_{18}Cl_2N_6O_2$ [$M + H$] $^+$ 482.3340 found 483.3344.

3.1.14. 5-Bromo-1-[1-[3-(7-chloro-quinolin-4-ylamino)-propyl]-1H-[1,2,3] triazol-4-ylmethyl]-1H-indole-2,3-dione (**8i**)

Red Solid; Yield: 72%; m.p. 178 °C (decomp.). IR (KBr) ν_{max} : 3359 (N–H), 1737 (C=O), 1607 (C=O) cm^{-1} ; 1H NMR (300 MHz $CDCl_3 + DMSO-d_6$): δ 2.21–2.25 (m, 2H, $-CH_2-$); 3.76–3.78 (m, 2H, $-N-CH_2-$); 4.60–4.62 (m, 2H, $-N-CH_2-$); 4.96 (s, 2H, $-N-CH_2-$); 6.29 (d, $J = 5.4$ Hz, 1H, H^2); 7.04 (d, 1H, $J = 8.4$ Hz, 1H, ArH, H^7); 7.13 (s, NH exchangeable with D_2O); 7.25 (d, $J = 8.7$ Hz, 1H, H^4); 7.38 (d, $J = 8.4$ Hz, 1H, ArH, H^6); 7.45 (d, $J = 1.8$ Hz, 1H, ArH, H^9); 7.71 (s, 1H, H^5); 7.83 (s, 1H, triazole H); 7.99 (d, $J = 8.7$ Hz, 1H, H^3); 8.24 (d,

$J = 5.1$ Hz, 1H, H^1); ^{13}C NMR (DMSO- d_6 , 75 MHz): δ ppm = 31.1, 35.5, 42.5, 48.7, 98.6, 111.1, 112.5, 117.2, 118.6, 123.4, 123.7, 124.2, 124.9, 127.0, 133.9, 141.4, 146.8, 148.6, 150.1, 151.2, 157.9, 160.3, 183.2. HRMS Calculated for $C_{23}H_{18}BrClN_6O_2$ [$M + H$] $^+$ 526.7850 found 526.7858.

3.1.15. 1-[1-[3-(7-Chloro-quinolin-4-ylamino)-propyl]-1H-[1,2,3] triazol-4-ylmethyl]-5-methyl-1H-indole-2,3-dione (**8j**)

Red Solid; Yield: 65%; m.p. 168 °C (decomp.). IR (KBr) ν_{max} : 3348 (N–H), 1732 (C=O), 1614 (C=O) cm^{-1} ; 1H NMR (300 MHz $CDCl_3 + DMSO-d_6$): δ 2.23 (s, 3H, $-CH_3$); 2.28–2.32 (m, 2H, $-CH_2-$); 3.71–3.73 (m, 2H, $-N-CH_2-$); 4.56–4.58 (m, 2H, $-N-CH_2-$); 4.80 (s, 2H, $-N-CH_2-$); 6.24 (d, $J = 5.4$ Hz, 1H, H^2); 7.01 (d, 1H, $J = 8.4$ Hz, 1H, ArH, H^7); 7.11 (s, NH exchangeable with D_2O); 7.23 (d, $J = 9.0$ Hz, 1H, H^4); 7.37–7.41 (d, $J = 8.4$ Hz, 1H, ArH, H^6); 7.44 (d, $J = 1.8$ Hz, 1H, ArH, H^9); 7.78 (s, 1H, H^5); 7.90 (s, 1H, triazole H); 8.01–8.05 (d, $J = 9.0$ Hz, 1H, H^3); 8.32 (d, $J = 5.1$ Hz, 1H, H^1); ^{13}C NMR (DMSO- d_6 , 75 MHz): δ ppm = 23.6, 31.4, 35.6, 42.3, 48.3, 98.6, 111.6, 112.7, 116.9, 118.5, 123.5, 123.8, 124.1, 124.6, 127.4, 134.2, 141.8, 146.5, 148.4, 150.8, 152.6, 158.8, 160.4, 182.0. HRMS Calculated for $C_{24}H_{21}ClN_6O_2$ [$M + H$] $^+$ 460.9155 found 460.9150.

Acknowledgements

Financial assistance from Board of Research in Nuclear Sciences under DAE Research Award for Young Scientist Scheme (VK) is gratefully acknowledged.

Appendix A. Supplementary material

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.ejmech.2013.01.032>.

References

- [1] (a) L.M.B. Ursos, P.D. Roepe, Med. Res. Rev. 22 (2002) 465–491; (b) A. Kumar, S.B. Latoya, A. Agarwal, P.M.S. Chauhan, Curr. Med. Chem. 10 (2003) 1137–1150; (c) A. Kumar, S.B. Katiyar, A. Agarwal, P.M.S. Chauhan, Drug Future 28 (2003) 243–255; (d) V. Kumar, A. Mahajan, K. Chibale, Bioorg. Med. Chem. 17 (2009) 2236–2275.
- [2] M. Schlitzer, Curr. Med. Chem. 2 (2007) 944–986.
- [3] H. Atamna, H. Ginsburg, J. Biol. Chem. 270 (1995) 24876–24883.
- [4] P. Cravo, R. Culleton, A. Afonso, I.D. Ferreira, V.E. Do Rosario, Anti Infect. Agents Med. Chem. 5 (2006) 63–73.
- [5] J. Wiesner, R. Ortmann, H. Jomaa, M. Schlitzer, Angew. Chem. Int. Ed. 42 (2003) 5274–5293.
- [6] D.L. Klayman, Science 228 (1985) 1049–1055.
- [7] A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phyto, J. Tarning, K.M. Lwin, F. Ariey, W. Hanpithakpong, S.J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S.S. An, S. Yeung, P. Singhasivanon, N.P. Day, N. Lindegardh, D. Socheat, N.J. White, N. Engl. J. Med. 361 (2009) 455–467.
- [8] V.V. Kouznetsov, A. Gomez-Barrio, Eur. J. Med. Chem. 44 (2009) 3091–3113.
- [9] T.J. Egan, Mini Rev. Med. Chem. 1 (2001) 113–123.
- [10] B. Meunier, Acc. Chem. Res. 41 (2008) 69–77.
- [11] J.J. Walsh, D. Coughlan, N. Heneghan, C. Gaynor, A. Bell, Bioorg. Med. Chem. Lett. 17 (2007) 3599–3602.
- [12] P. Beagley, M.A.L. Blackie, K. Chibale, C. Clarkson, R. Meijboom, J.R. Moss, P.J. Smith, H. Su, Dalton Trans. 15 (2003) 3046–3051.
- [13] S.N. Pandeya, S. Smitha, M. Jyoti, S.K. Sridhar, Acta Pharm. 55 (2005) 27–46.
- [14] K.L. Vine, L. Matesic, J.M. Locke, M. Ranson, D. Skropeta, Anti Cancer Agents Med. Chem. 9 (2009) 397–414.
- [15] J. Ma, S. Li, K. Reed, P. Guo, J.M. Gallo, J. Pharmacol. Exp. Ther. 305 (2003) 833–839.
- [16] (a) D. Sriram, Y. Perumal, Curr. Med. Chem. 10 (2003) 1689–1695; (b) M.C. Pirrung, S.V. Pansare, K. Das Sarma, K.A. Keith, E.R. Kern, J. Med. Chem. 48 (2005) 3045–3050; (c) T.R. Bal, B. Anand, P. Yogeeswari, D. Sriram, Bioorg. Med. Chem. Lett. 15 (2005) 4451–4455.
- [17] D. Sriram, P. Yogeeswari, G. Gopal, Eur. J. Med. Chem. 40 (2005) 1373–1376.
- [18] S.N. Pandeya, D. Sriram, G. Nath, E. De Clercq, Arzneim. Forsch./Drug Res. 50 (2000) 55–59.

- [19] S.P. Kumar, J. Gut, R.C. Guedes, P.J. Rosenthal, M.M.M. Santos, R. Moreira, *Eur. J. Med. Chem.* 46 (2011) 927–933.
- [20] P. Singh, S. Sachdeva, R. Raj, V. Kumar, M.P. Mahajan, S. Nasser, L. Vivas, J. Gut, P.J. Rosenthal, T.S. Feng, K. Chibale, *Bioorg. Med. Chem. Lett.* 21 (2011) 4561–4563.
- [21] (a) K. Kumar, S. Sagar, L. Esau, M. Kaur, V. Kumar, *Eur. J. Med. Chem.* 58 (2012) 153–159;
(b) P. Singh, R. Raj, V. Kumar, M.P. Mahajan, P.M.S. Bedi, T. Kaur, A.K. Saxena, *Eur. J. Med. Chem.* 47 (2012) 594–600;
(c) M.N. Aminake, A. Mahajan, V. Kumar, R. Hans, L. Wiesner, D. Taylor, C. de Kock, A. Grobler, P.J. Smith, M. Kirschner, A. Rethwilm, G. Pradel, K. Chibale, *Bioorg. Med. Chem.* 20 (2012) 5277–5289;
(d) K. Kumar, P. Singh, L. Kremer, Y. Guérardel, C. Biot, V. Kumar, *Dalton Trans.* 41 (2012) 5778–5781;
(e) K. Kumar, S.C. Kremer, L. Kremer, Y. Guérardel, C. Biot, V. Kumar, *Dalton Trans.* 2013. <http://dx.doi.org/10.1039/C2DT32148C>.
- [22] H.C. Kolb, K.B. Sharpless, *Drug Discov. Today* 8 (2003) 1128–1137.
- [23] P. Singh, P. Sharma, A. Anand, P.M.S. Bedi, T. Kaur, A.K. Saxena, V. Kumar, *Eur. J. Med. Chem.* 55 (2012) 455–461.
- [24] M.V.N. De Souza, K.C. Pais, C.R. Kaiser, M.A. Peralta, M. de L. Ferreira, M.C.S. Lourenco, *Bioorg. Med. Chem.* 17 (2009) 1474–1480.
- [25] I. Chiyanzu, C. Clarkson, P.J. Smith, J. Lehman, J. Gut, P.J. Rosenthal, K. Chibale, *Bioorg. Med. Chem.* 13 (2005) 3249–3261.
- [26] J.B. Jensen, *In vitro* culture of plasmodium parasites, in: D.L. Doolan (Ed.), *Malaria Methods and Protocols*, Humana, Totowa, NJ, 2002, pp. 477–488.
- [27] A. Singh, P.J. Rosenthal, *Antimicrob. Agents Chemother.* 45 (2001) 949–951.